Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial

伯氨喹 青蒿琥酯 医学 甲氟喹 蒿甲醚 阿莫地喹 哌喹 羽扇豆碱 蒿甲醚/麝香草醚 疟疾 青蒿素 固定剂量组合 双氢青蒿素 内科学 恶性疟原虫 药理学 氯喹 免疫学
作者
Frank Smithuis,Moe Kyaw Kyaw,Ohn Phe,Thein Win,Pyay Phyo Aung,Aung Pyay Phyo Oo,Arkar Linn Naing,Mya Yee Nyo,Naing Zaw Htun Myint,Mallika Imwong,Elizabeth A. Ashley,Sue J. Lee,Nicholas J. White
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:10 (10): 673-681 被引量:173
标识
DOI:10.1016/s1473-3099(10)70187-0
摘要

BackgroundArtemisinin-combination therapy (ACT) is recommended as first-line treatment of falciparum malaria throughout the world, and fixed-dose combinations are preferred by WHO; whether a single gametocytocidal dose of primaquine should be added is unknown. We aimed to compare effectiveness of four fixed-dose ACTs and a loose tablet combination of artesunate and mefloquine, and assess the addition of a single gametocytocidal dose of primaquine.MethodsIn an open-label randomised trial in clinics in Rakhine state, Kachin state, and Shan state in Myanmar (Burma) between Dec 30, 2008, and March 20, 2009, we compared the effectiveness of all four WHO-recommended fixed-dose ACTs (artesunate–mefloquine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, artemether–lumefantrine) and loose artesunate–mefloquine in Burmese adults and children. Eligible patients were those who presented to the clinics with acute uncomplicated Plasmodium falciparum malaria or mixed infection, who were older than 6 months, and who weighed more than 5 kg. Treatments were randomised in equal numbers within blocks of 50 and allocation was in sealed envelopes. All patients were also randomly assigned to receive either a single dose of primaquine 0·75 mg base/kg or not. Patients were followed up for 63 days. Treatment groups were compared by analysis of variance and multiple logistic regression. The primary outcome was the 63 day recrudescence rate. This study is registered with clinicaltrials.gov, number NCT00902811.Findings155 patients received artesunate–amodiaquine, 162 artemether–lumefantrine, 169 artesunate–mefloquine, 161 loose artesunate–mefloquine, and 161 dihydroartemisinin–piperaquine. By day 63 of follow-up, 14 patients (9·4%; 95% CI 5·7–15·3%) on artesunate–amodiaquine had recrudescent P falciparum infections, a rate significantly higher than for artemether–lumefantrine (two patients; 1·4%; 0·3–5·3; p=0·0013), fixed-dose artesunate–mefloquine (0 patients; 0–2·3; p<0·0001), loose artesunate–mefloquine (two patients; 1·3%; 0·3–5·3; p=0·0018), and dihydroartemisinin–piperaquine (two patients 1·3%; 0·3–5·2%; p=0·0012). Hazard ratios for re-infection (95% CI) after artesunate–amodiaquine were 3·2 (1·3–8·0) compared with the two artesunate–mefloquine groups (p=0·01), 2·6 (1·0–6–0) compared with artemether–lumefantrine (p=0·04), and 2·3 (0·9–6·0) compared with dihydroartemisinin–piperaquine (p=0·08). Mixed falciparum and vivax infections were common: 129 (16%) had a mixed infection at presentation and 330 (41%) patients had one or more episodes of Plasmodium vivax infection during follow-up. The addition of a single dose of primaquine (0·75 mg/kg) reduced P falciparum gametocyte carriage substantially: rate ratio 11·9 (95% CI 7·4–20·5). All regimens were well tolerated. Adverse events were reported by 599 patients, most commonly vomiting and dizziness. Other side-effects were less common and were not related to a specific treatment.InterpretationArtesunate–amodiaquine should not be used in Myanmar, because the other ACTs are substantially more effective. Artesunate–mefloquine provided the greatest post-treatment suppression of malaria. Adding a single dose of primaquine would substantially reduce transmission potential. Vivax malaria, not recurrent falciparum malaria, is the main complication after treatment of P falciparum infections in this region.FundingMédecins sans Frontières (Holland) and the Wellcome Trust Mahidol University Oxford Tropical Medicine Research Programme.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
核桃应助钱浩然采纳,获得10
刚刚
刚刚
脑洞疼应助张张张哈哈哈采纳,获得10
刚刚
1秒前
颠覆乾坤发布了新的文献求助10
2秒前
小王加油啊啊啊完成签到 ,获得积分10
2秒前
虚幻沛文完成签到 ,获得积分10
3秒前
hua完成签到 ,获得积分10
3秒前
zyf发布了新的文献求助10
4秒前
Ray完成签到,获得积分10
5秒前
yukiseto完成签到 ,获得积分10
5秒前
caozhi完成签到,获得积分10
5秒前
有魅力的发卡完成签到,获得积分10
6秒前
包容的若风完成签到,获得积分10
6秒前
szxnb666完成签到,获得积分20
7秒前
开心薯片完成签到,获得积分10
7秒前
HHH完成签到,获得积分10
8秒前
黑黑黑完成签到,获得积分10
9秒前
Kelly1426完成签到,获得积分10
10秒前
海边的曼彻斯特完成签到 ,获得积分10
10秒前
turbohero完成签到,获得积分10
10秒前
量子星尘发布了新的文献求助10
11秒前
英俊的铭应助开心薯片采纳,获得10
11秒前
12秒前
八月宁静完成签到,获得积分10
13秒前
小曾完成签到,获得积分10
13秒前
zyf完成签到,获得积分10
14秒前
高山流水完成签到,获得积分10
14秒前
咎淇完成签到,获得积分10
14秒前
kilig完成签到 ,获得积分10
15秒前
顾矜应助烊烊采纳,获得10
15秒前
平平无奇打工人完成签到 ,获得积分10
18秒前
Young完成签到 ,获得积分10
19秒前
陳某完成签到,获得积分10
20秒前
赖道之发布了新的文献求助10
21秒前
一区的王完成签到 ,获得积分10
22秒前
搬砖的化学男完成签到 ,获得积分0
23秒前
满意的迎南完成签到 ,获得积分10
23秒前
wang完成签到,获得积分10
23秒前
Lynn完成签到 ,获得积分10
29秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022